Stock slumps for Tel Aviv's Galmed following PhIIa NAFLD flop
The stock price is cratering for thinly-traded Tel Aviv company Galmed Pharmaceuticals $GLMD, which just announced a Phase IIa letdown of its non-alcoholic fatty liver disease program.
The mid-stage study was evaluating Aramchol in 50 patients with HIV-associated lipodystrophy and non-alcoholic fatty liver disease. The study, called Arrive, failed to meet the primary endpoint of an improvement in liver fat at week 12.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.